TNXP
Tonix Pharmaceuticals Holding Corp. [TNXP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TNXP Stock Summary
Top 10 Correlated ETFs
TNXP
Top 10 Correlated Stocks
TNXP
In the News
Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit
CHATHAM, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the June 1st Virtual Investor Summit on Thursday, June 1, 2023, at 10:30 a.m. ET.
Tonix Pharmaceuticals exec presents data on Prader-Willi Syndrome drug at rare disease conference
Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp EVP of translation medicine Herbert Harris delivered an oral presentation Thursday at the Rare Disease Innovation and Partnership Summit in Philadelphia, the company announced. The presentation, titled, “TNX-2900 (Intranasal Potentiated Oxytocin) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome,” includes data showing the enhancing effects of magnesium on the activation of oxytocin receptors.
Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit
CHATHAM, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday, March 29, 2023, at 9:00 a.m. ET.
Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodies
Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. said it has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies (mAbs) for the treatment or prophylaxis of SARS-CoV-2 infection. SARS-CoV-2 is the cause of COVID-19.
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.
Using News to Find Penny Stocks to Buy: 3 Tips
Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Tonix Pharmaceuticals to Present at Biotech Showcase 2023
CHATHAM, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at Biotech Showcase 2023 being held January 9-11, 2023, at the Hilton San Francisco Union Square.
How to Conduct Due Diligence on Penny Stocks, 3 Tips
Need help researching penny stocks to buy? Use these tips The post How to Conduct Due Diligence on Penny Stocks, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?
Today is a banner day for anyone who happened to hold Tonix Pharmaceuticals (NASDAQ: TNXP ) stock over the weekend. Early this morning, Tonix disclosed an exclusive license with a drug developer which could produce an entirely new approach to treating Covid-19.
Tonix Pharmaceuticals to Present at the 2022 BioFuture Conference
CHATHAM, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at BioFuture on Tuesday, November 8, 2022, at 11:00 a.m. ET, and host investor meetings. The conference is being held at the Lotte New York Palace in New York City.
TNXP Financial details
TNXP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -238.29 | -3.53K | -106.54 | -8.1 | -3.22 | |
| Operating cash flow per share | -218.94 | -3.32K | -102.69 | -6.64 | -2.74 | |
| Free cash flow per share | -219 | -3.32K | -120.79 | -9.74 | -4.09 | |
| Cash per share | 228.65 | 1.4K | 162.95 | 15.69 | 3.36 | |
| Book value per share | 216.14 | 1.17K | 185.32 | 19.21 | 5.8 | |
| Tangible book value per share | 215.04 | 1.17K | 185.32 | 19.21 | 5.8 | |
| Share holders equity per share | 216.14 | 1.17K | 185.32 | 19.21 | 5.8 | |
| Interest debt per share | 0 | 44.52 | 2.77 | 0.08 | -0.2 | |
| Market cap | 481.74M | 1.88M | 63.85M | 814.64M | 87.07M | |
| Enterprise value | 456.7M | -9.01M | -11.91M | 636.93M | -32.4M | |
| P/E ratio | -18.47 | -0.07 | -1.27 | -8.83 | -0.76 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -20.1 | -0.07 | -1.31 | -10.78 | -0.89 | |
| PFCF ratio | -20.09 | -0.07 | -1.12 | -7.35 | -0.6 | |
| P/B Ratio | 20.36 | 0.2 | 0.73 | 3.72 | 0.42 | |
| PTB ratio | 20.36 | 0.2 | 0.73 | 3.72 | 0.42 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -17.54 | 0.31 | 0.24 | -6.9 | 0.29 | |
| EV to operating cash flow | -19.05 | 0.34 | 0.25 | -8.43 | 0.33 | |
| EV to free cash flow | -19.05 | 0.34 | 0.21 | -5.75 | 0.22 | |
| Earnings yield | -0.05 | -15.08 | -0.79 | -0.11 | -1.32 | |
| Free cash flow yield | -0.05 | -14.19 | -0.89 | -0.14 | -1.68 | |
| Debt to equity | 0.11 | 0.55 | 0.12 | 0.1 | 0.09 | |
| Debt to assets | 0.1 | 0.35 | 0.11 | 0.09 | 0.08 | |
| Net debt to EBITDA | 0.96 | 0.38 | 1.5 | 1.93 | 1.07 | |
| Current ratio | 9.81 | 2.72 | 8.96 | 8.71 | 7.19 | |
| Interest coverage | 0 | 0 | 0 | 1.85K | 14.17 | |
| Income quality | 0.92 | 0.93 | 0.96 | 0.82 | 0.89 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.08 | |
| Payout ratio | 0 | 0 | 0 | 0 | -0.06 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.01 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.18 | 0.47 | 0.49 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.11 | -0.65 | -317.19 | -706.14 | -38.43 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.08K | 9.64K | 666.5 | 59.17 | 20.49 | |
| ROIC | 1.05 | 2.6 | 0.83 | 0.71 | 5.12 | |
| Return on tangible assets | -1 | -1.97 | -0.51 | -0.38 | -0.51 | |
| Graham Net | 208 | 853.8 | 152.77 | 14.25 | 3.01 | |
| Working capital | 23.4M | 8.81M | 78.17M | 167.33M | 112.6M | |
| Tangible asset value | 23.54M | 9.3M | 87.53M | 218.6M | 207.18M | |
| Net current asset value | 23.4M | 8.81M | 77.45M | 166.87M | 112.27M | |
| Invested capital | 0 | 0.04 | 0.01 | 0 | 0 | |
| Average receivables | 509.5K | 768K | 4.32M | 7.68M | 7.88M | |
| Average payables | 1.35M | 2.24M | 3.83M | 8.94M | 10.68M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.1 | -3.01 | -0.57 | -0.42 | -0.56 | |
| Capex per share | -0.05 | -2.11 | -18.11 | -3.1 | -1.35 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0.4 | 0.23 | 0 | 0 | |
| Net income per share | -1.62 | -1.02 | -0.68 | -0.61 | -3.08 | |
| Operating cash flow per share | -1.9 | -0.94 | -0.56 | -0.36 | -3.25 | |
| Free cash flow per share | -3.14 | -1.59 | -0.77 | -0.44 | -3.62 | |
| Cash per share | 8.61 | 6.49 | 3.34 | 1.96 | 7.1 | |
| Book value per share | 12.75 | 10.19 | 5.46 | 3.38 | 16.32 | |
| Tangible book value per share | 12.75 | 10.19 | 5.46 | 3.38 | 16.32 | |
| Share holders equity per share | 12.75 | 10.19 | 5.46 | 3.38 | 16.32 | |
| Interest debt per share | 0.05 | 0.05 | 0.04 | 0 | -0.08 | |
| Market cap | 751.14M | 221.24M | 140.04M | 149.53M | 37.45M | |
| Enterprise value | 611.51M | 76.75M | 951.59K | 30.06M | -33.5M | |
| P/E ratio | -7.11 | -2.41 | -1.23 | -1 | -0.3 | |
| Price to sales ratio | 0 | 24.51 | 14.38 | 0 | 0 | |
| POCF ratio | -24.19 | -10.45 | -5.95 | -6.71 | -1.14 | |
| PFCF ratio | -14.65 | -6.21 | -4.33 | -5.54 | -1.02 | |
| P/B Ratio | 3.61 | 0.97 | 0.61 | 0.72 | 0.23 | |
| PTB ratio | 3.61 | 0.97 | 0.61 | 0.72 | 0.23 | |
| EV to sales | 0 | 8.5 | 0.1 | 0 | 0 | |
| Enterprise value over EBITDA | -23.13 | -3.29 | -0.03 | -0.92 | 0.99 | |
| EV to operating cash flow | -19.7 | -3.63 | -0.04 | -1.35 | 1.02 | |
| EV to free cash flow | -11.93 | -2.16 | -0.03 | -1.11 | 0.91 | |
| Earnings yield | -0.04 | -0.1 | -0.2 | -0.25 | -0.83 | |
| Free cash flow yield | -0.07 | -0.16 | -0.23 | -0.18 | -0.98 | |
| Debt to equity | 0.08 | 0.21 | 0.06 | 0.09 | 0.08 | |
| Debt to assets | 0.07 | 0.17 | 0.06 | 0.08 | 0.08 | |
| Net debt to EBITDA | 5.28 | 6.19 | 4.74 | 3.65 | 2.09 | |
| Current ratio | 9.96 | 12.05 | 11.33 | 7.19 | 6.4 | |
| Interest coverage | -1.39K | -119.06 | -48.51 | 39.67 | 18.94 | |
| Income quality | 1.18 | 0.91 | 0.81 | 0.7 | 1 | |
| Dividend Yield | 0 | 0.02 | 0 | 0.02 | 0 | |
| Payout ratio | 0 | -0.19 | 0 | -0.06 | 0 | |
| Sales general and administrative to revenue | 0 | 0.75 | 0.76 | 0 | 0 | |
| Research and developement to revenue | 0 | 1.84 | 2.28 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.65 | 0.68 | 0.37 | 0.21 | 0.12 | |
| Capex to revenue | 0 | -1.6 | -0.91 | 0 | 0 | |
| Capex to depreciation | -320.9 | -141.56 | -35 | -5.59 | -4.25 | |
| Stock based compensation to revenue | 0 | 0.31 | 0.28 | 0 | 0 | |
| Graham number | 21.54 | 15.32 | 9.11 | 6.79 | 33.63 | |
| ROIC | 0.4 | 0.95 | 0.69 | 1.69 | -1.18 | |
| Return on tangible assets | -0.12 | -0.08 | -0.12 | -0.17 | -0.17 | |
| Graham Net | 7.64 | 4.36 | 3.01 | 1.76 | 5.75 | |
| Working capital | 137.64M | 175.84M | 137.8M | 112.6M | 70.65M | |
| Tangible asset value | 207.96M | 228.28M | 228.92M | 207.18M | 165.43M | |
| Net current asset value | 137.23M | 143.86M | 137.42M | 112.27M | 70.07M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.01 | |
| Average receivables | 3.86M | 0 | 0 | 4.02M | 4.02M | |
| Average payables | 11.34M | 9.48M | 7.06M | 6.31M | 8.04M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | -21.28 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | -4.23 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.13 | -0.1 | -0.12 | -0.18 | -0.19 | |
| Capex per share | -1.24 | -0.64 | -0.21 | -0.08 | -0.37 |
TNXP Frequently Asked Questions
What is Tonix Pharmaceuticals Holding Corp. stock symbol ?
Tonix Pharmaceuticals Holding Corp. is a US stock , located in Chatham of Nj and trading under the symbol TNXP
What is Tonix Pharmaceuticals Holding Corp. stock quote today ?
Tonix Pharmaceuticals Holding Corp. stock price is $1.88 today.
Is Tonix Pharmaceuticals Holding Corp. stock public?
Yes, Tonix Pharmaceuticals Holding Corp. is a publicly traded company.
Company Profile
- Volume Average 217.23K
- Market Capitalization 19.44M
- Employee 117
- CEO Dr. Seth Lederman M.D.
- Headquarters Chatham,NJ,US
- IPO Date 2010-03-29
-
Website
https://www.tonixpharma.com 
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
